One2Treat's team

Marc Buyse is a leading figure in clinical research, renowned for founding IDDI and CluePoints. With decades of academic experience, he has spearheaded innovative methodologies for personalized medicine, meta-analysis, and surrogate endpoints. Marc's expertise in biostatistics has driven advancements in data-driven decision-making and patient-centric trial design. As the founder of One2Treat, he continues to lead innovation in clinical research methodologies and technologies, focusing on SaaS solutions for trial design and analysis while prioritizing patients' needs and clinical relevance at the forefront of every discussion and decision.

Pascal Piedbois, professor of medical oncology, offers considerable experience from both the academic and industry sectors. In academia, he served as the Head of Medical Oncology at Paris University and was the General Director of the Comprehensive Cancer Center of the Alsace Region, based in Strasbourg, until 2015. In the industry, Pascal has held several prominent leadership roles, including Vice President, Head of Global Oncology and Infectious Diseases at AstraZeneca, Senior Vice President, Head of Medical Europe, Canada, and Japan, and Senior Vice President, Head of Medical Go To Market Strategy for Bristol Myers Squibb. Additionally, he has served as the General Manager of Boehringer-Ingelheim Belgium. Pascal’s passion and commitment to combining digital innovation with medical relevance is set to enable the incorporation of patient preferences and needs into the development and market access of new treatments.

Sebastien Coppe brings extensive expertise in the field of clinical trials and artificial intelligence. Over the course of more than a decade at N-SIDE, he played a pivotal role in leading the company's Life Sciences activities, contributing significantly to its growth from a small start-up to a purpose-driven organization with over 200 employees. With a deep understanding of the biopharma industry's challenges and opportunities, Sebastien made the bold decision to join Marc Buyse in his latest venture, aiming to industrialize his paradigm-shifting solution that enhances treatment decisions. Sebastien is driven by a strong conviction in the potential of innovative digital solutions to meet the overall patients’ needs and accelerate clinical research timelines. He is committed to pioneering approaches that prioritize patient-centricity and enhance biopharma productivity.

Emilie Barré offers over 18 years of rich experience in clinical trials, blending her statistical expertise with seasoned project management skills. Throughout her career, including a significant period at BMS, Emilie has developed both the analytical and leadership aspects necessary for success in the field. Emilie's approach centers on creating genuine partnerships with clients, striving to deeply understand and meet their needs. This dedication to client service, combined with her extensive background, enables her to lead projects that deliver meaningful and tailored healthcare solutions.

Jean-Christophe Chiêm earned a master's degree in civil engineering in applied mathematics and gained previous experience in consulting for the industry (Solvay, Bosch). Driven by his desire to make a meaningful contribution to his social values, he pursued a PhD in public health, focusing on simulations of complex healthcare topics. Joining IDDI as a biostatistician in 2015, he developed a passion for a patient-centered approach in clinical trials. Since 2019, he has been teaching statistics at the School of Public Health at ULB. Presently, he coordinates the development of software solutions at One2Treat.

Samuel Salvaggio translates clinical outcomes into statistical insights, utilizing his expertise in data analytics and applied biostatistics. His dedication to advancing patient-focused research is evident through his work, including scientific publications and educational efforts. At One2Treat, Samuel's passion fuels innovative research initiatives, while his teaching role at the Université libre de Bruxelles allows him to share his applied biostatistics expertise with medical professionals. This blend of professional activities underscores his commitment to enhancing patient-centric solutions through education and innovative research.

Rudradev Sengupta is an accomplished biostatistician with a Ph.D. in Statistics and over a decade of experience in the pharmaceutical industry. He specializes in translating complex biostatistical data into actionable healthcare insights, with profound expertise in statistical modeling, advanced analytics, and computing. His numerous scientific publications reflect his dedication to advancing healthcare through rigorous methodologies. At One2Treat, Rudradev leverages his expertise to design patient-centric clinical trials, ensuring that innovative treatments are developed with the utmost precision and relevance. In addition to his professional endeavors, Rudradev is committed to academic excellence, teaching, and mentoring the next generation of biostatisticians at UHasselt.

Sarah Kosta has a background in biophysics and is committed to leveraging technology to enhance clinical trials. Specialized in statistical programming, she offers her expertise to assist customers in defining innovative clinical software solutions. As clinical trial processes are moving toward a patient-centric approach, she focuses on programming solutions that prioritize the needs of both patients and clinical investigators, ensuring they meet the evolving needs of clinical trial submissions. Empowering patients through high-quality and carefully designed technology solutions is her core value to pave the way for more effective treatments and improved patient outcomes.

Hatem Alharazin brings diverse skills to clinical trial processes, with his expertise in statistics and data science, and over a decade of professional experience spanning research, statistical analysis, and academic teaching, dedicating to revolutionize clinical trial analysis. At One2Treat, Hatem is committed to harness his proficiency in modern technologies to translate complex clinical data to impactful insights. ensuring that clinical trials are both efficient and patient centric. His generosity standing on a solid ground to prioritize patient needs and safety, through driving innovation in clinical research.

Tom Mann brings over 15 years of experience in tech start-ups and scale-ups, where he played a pivotal role in driving customer engagement, marketing initiatives, and strategic partnerships. At One2Treat, Tom's expertise and fresh perspective are invaluable as we continue to develop solutions that integrate key patient-relevant outcomes into a single holistic treatment assessment. With a strong background in SaaS companies, Tom has a deep understanding of customer needs. His ability to translate those needs into actionable solutions will be essential in expanding One2Treat’s reach and impact within the clinical research landscape. At the same time, he ensures that our approach remains both innovative and patient-focused.

Mathilde Tournay is an experienced biostatistician who joined us from our sister company IDDI, where she applied advanced statistical methodologies to clinical trial data. With dual Master’s degrees in Bioscience Engineering and Statistics from UCLouvain, she has a strong interdisciplinary foundation bridging biological sciences and complex data analysis. At One2Treat, she leverages her expertise to design clinical trials that are both scientifically rigorous and aligned with patient needs, playing a vital role in advancing our mission to prioritize patients in every aspect of clinical research.